Skip to main content
Clinical Trials/JPRN-UMIN000043049
JPRN-UMIN000043049
Completed
未知

A multi-center retrospective observational study in patients with relapsed and refractory multiple myeloma receiving once-weekly carfilzomib dosing in combination with dexamethasone in a real-world setting in Japan (Weekly-CAR study) - Weekly-CAR study

Ono Pharmaceutical Co., Ltd.0 sites150 target enrollmentJanuary 19, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Multiple myeloma
Sponsor
Ono Pharmaceutical Co., Ltd.
Enrollment
150
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 19, 2021
End Date
March 31, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • \-Patients with hypersensitivity to ingredients of carfilzomib and dexamethasone \-Pregnant women \-Patients with initial doses of carfilzomib other than 20 mg/m2 \-Patients with a history of recent administration of carfilzomib \[Patients who have not been treated with carfilzomib for at least 6 months between the last dose of carfilzomib and the first dose of wKd therapy.]

Outcomes

Primary Outcomes

Not specified

Similar Trials